Noetik Selected for AWS Generative AI Accelerator
Noetik, a pioneering AI-driven biotechnology company, has officially announced its participation in the renowned AWS Generative AI Accelerator. This program, created by Amazon Web Services (AWS), aims to support early-stage startups that use generative AI technologies to tackle complex issues in various fields.
Empowering Cancer Therapeutics
Noetik focuses on utilizing self-supervised machine learning and high-throughput spatial data to create next-generation cancer therapies. By joining the accelerator, the company hopes to bolster its abilities in building and refining cutting-edge generative models tailored for precision cancer treatment.
Access to Resources and Expertise
As a participant in the AWS Generative AI Accelerator, Noetik will receive valuable AWS credits, personalized mentorship, and access to a wealth of learning resources. These offerings are specifically designed to aid the company in expanding its use of artificial intelligence (AI) and machine learning (ML) in its revolutionary research on cancer treatments.
Advancements in Cancer Drug Discovery
Noetik’s innovative approach revolves around its OCTO model, a custom vision transformer that analyzes proprietary human data generated in-house. The main goal of OCTO is to answer the crucial question of “which drug for which patients,” acting as a discovery engine to identify promising cancer therapeutics and predict clinical responses.
Scaling Through Series A Financing
Following a successful $40 million Series A financing round, Noetik is prepared to significantly boost the scale of both its datasets and models. This expansion is viewed as vital for allowing its models to develop a deep understanding of biological systems, thereby enhancing the discovery process for precision cancer therapies.
Ambitious Growth Plans
Importantly, Noetik's existing models already exceed the scale of the initial AlphaFold models, demonstrating remarkable proficiency in comprehending cancer biology and immunology. The team aims to increase model sizes and GPU utilization by up to 50 times this year. Collaborating with AWS through the Generative AI Accelerator will help address technical challenges and improve the complexity of models representing cancer biology.
Leadership Perspectives
Lacey Padron, Noetik's Chief Technology Officer, emphasized the importance of entering the AWS Generative AI Accelerator: “This is an extraordinary opportunity. Our technological capabilities far surpass those of most AI applications in biological sciences, and we eagerly look forward to leveraging AWS's advanced technology to enhance our model scale and its impact on cancer patients.”
Networking Opportunities at re:Invent 2024
A standout feature of the accelerator program is that all global startups will present their innovative solutions to a diverse audience of investors, customers, partners, and AWS representatives at this December's re:Invent 2024 event in Las Vegas.
Transformative Startup Ecosystem
In discussing the program, Jon Jones, Vice President of Go-to-Market at AWS, remarked, “This new generation of startups is leading a transformative wave, pushing the boundaries of artificial intelligence while introducing new solutions to the market. Our decision to expand our accelerator cohort highlights the vast potential we see in startups poised to bring cutting-edge innovations to an AI-driven world. AWS is dedicated to nurturing these groundbreaking technologies and supporting visionary entrepreneurs as they set out to address significant global challenges.”
About Noetik
Noetik operates at the crossroads of artificial intelligence and biotechnology. By utilizing self-supervised learning along with human multimodal data, the company aims to discover better precision therapies. Based in San Francisco, California, Noetik is focused on achieving transformative advancements in cancer treatment through its proprietary technologies.
Frequently Asked Questions
What is the AWS Generative AI Accelerator?
The AWS Generative AI Accelerator is a program that supports early-stage startups using generative AI to solve complex issues by offering resources such as AWS credits and mentorship.
What is the purpose of Noetik's OCTO model?
Noetik's OCTO model serves as a discovery engine to identify promising cancer therapeutics and predict clinical responses based on patient data.
How has Noetik funded its growth?
Noetik recently concluded a $40 million Series A financing round, enabling it to expand its datasets and model capacities significantly.
What are the future plans for Noetik?
Moving forward, Noetik aims to increase its model sizes and GPU utilization by as much as 50 times, enhancing its capacity to develop precision cancer therapies.
What impact does the accelerator program have?
Participation in the accelerator program allows Noetik to address technical challenges and push the limits of AI applications in cancer research, ultimately benefiting patient outcomes.
